JP2022542804A5 - - Google Patents

Info

Publication number
JP2022542804A5
JP2022542804A5 JP2022502218A JP2022502218A JP2022542804A5 JP 2022542804 A5 JP2022542804 A5 JP 2022542804A5 JP 2022502218 A JP2022502218 A JP 2022502218A JP 2022502218 A JP2022502218 A JP 2022502218A JP 2022542804 A5 JP2022542804 A5 JP 2022542804A5
Authority
JP
Japan
Prior art keywords
approximately
weight
sodium
iii
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022502218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542804A (ja
JP7623342B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/042389 external-priority patent/WO2021011808A1/en
Publication of JP2022542804A publication Critical patent/JP2022542804A/ja
Publication of JP2022542804A5 publication Critical patent/JP2022542804A5/ja
Application granted granted Critical
Publication of JP7623342B2 publication Critical patent/JP7623342B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022502218A 2019-07-17 2020-07-16 心臓サルコメア阻害剤の経口用製剤 Active JP7623342B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875358P 2019-07-17 2019-07-17
US62/875,358 2019-07-17
PCT/US2020/042389 WO2021011808A1 (en) 2019-07-17 2020-07-16 Cardiac sarcomere inhibitor oral formulations

Publications (3)

Publication Number Publication Date
JP2022542804A JP2022542804A (ja) 2022-10-07
JP2022542804A5 true JP2022542804A5 (cg-RX-API-DMAC7.html) 2023-07-25
JP7623342B2 JP7623342B2 (ja) 2025-01-28

Family

ID=71995104

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502218A Active JP7623342B2 (ja) 2019-07-17 2020-07-16 心臓サルコメア阻害剤の経口用製剤

Country Status (24)

Country Link
US (1) US20220265612A1 (cg-RX-API-DMAC7.html)
EP (1) EP3999038B1 (cg-RX-API-DMAC7.html)
JP (1) JP7623342B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220082804A (cg-RX-API-DMAC7.html)
CN (1) CN114765954B (cg-RX-API-DMAC7.html)
AU (1) AU2020315642B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022000495A2 (cg-RX-API-DMAC7.html)
CL (1) CL2022000108A1 (cg-RX-API-DMAC7.html)
DK (1) DK3999038T3 (cg-RX-API-DMAC7.html)
ES (1) ES2974542T3 (cg-RX-API-DMAC7.html)
FI (1) FI3999038T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240200T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065712T2 (cg-RX-API-DMAC7.html)
IL (1) IL289884B2 (cg-RX-API-DMAC7.html)
LT (1) LT3999038T (cg-RX-API-DMAC7.html)
MX (1) MX2022000708A (cg-RX-API-DMAC7.html)
PH (1) PH12022550083A1 (cg-RX-API-DMAC7.html)
PL (1) PL3999038T3 (cg-RX-API-DMAC7.html)
PT (1) PT3999038T (cg-RX-API-DMAC7.html)
RS (1) RS65302B1 (cg-RX-API-DMAC7.html)
SI (1) SI3999038T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400107T1 (cg-RX-API-DMAC7.html)
TW (2) TW202519217A (cg-RX-API-DMAC7.html)
WO (1) WO2021011808A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
US20240091203A1 (en) 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
JP2025525913A (ja) 2022-08-04 2025-08-07 サイトキネティックス, インコーポレイテッド 閉塞性肥大型心筋症を治療するための方法
CN120712262A (zh) * 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
WO2025198687A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006284751A1 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CA2772275A1 (en) * 2009-09-18 2011-03-24 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
US20130273096A1 (en) * 2011-10-05 2013-10-17 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
NZ727015A (en) * 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US9199945B2 (en) * 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
EP3151671A4 (en) * 2014-06-03 2018-03-07 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
DK3356345T3 (da) * 2015-09-30 2024-02-12 Max Planck Gesellschaft Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
SG11202006296YA (en) * 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Similar Documents

Publication Publication Date Title
FI3999038T3 (fi) Sydämen sarkomeerin inhibiittorin oraalisia formulaatioita
US11819577B2 (en) Fixed dose pharmaceutical composition of valsartan and sacubitril
RU2376988C2 (ru) Фармацевтические композиции замедленного высвобождения, содержащие аплиндор и его производные
US20180360761A1 (en) Pharmaceutical composition comprising a potent inhibitor of urat1
US10603282B2 (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
WO2017208136A1 (en) Pharmaceutical composition of dapagliflozin co-crystal
US20200368185A1 (en) Combination formulation containing sustained release metformin and immediate release hmg-coa reductase inhibitor
US11576917B2 (en) Pharmaceutical compositions comprising Ibrutinib
US20210267908A1 (en) Pharmaceutical compositions of rivaroxaban
JP2023548855A5 (cg-RX-API-DMAC7.html)
US9561242B2 (en) Doxycycline composition
WO2022153330A1 (en) Pharmaceutical compositions comprising acalabrutinib
WO2007049291A1 (en) Novel solid dosage forms of valsartan and rochlorothiazide
RU2022103864A (ru) Пероральные композиции ингибиторов сердечного саркомера
CN114173786A (zh) 包含hmg-辅酶a还原酶抑制剂和非诺贝特的药物组合物
US20120121722A1 (en) Atazanavir formulations
US9566287B2 (en) Pharmaceutical composition of doxycycline with reduced food effect
WO2025132571A1 (en) Immediate release monolayer tablet comprising telmisartan and one or more other antihypertensive agents, method of manufacturing the same, and its use
KR20090107960A (ko) 심혈관계 질환 치료용 약제학적 제제
JP2021091624A (ja) ソラフェニブトシル酸塩製剤
NZ784934B2 (en) Cardiac sarcomere inhibitor oral formulations
KR20230096906A (ko) 페노피브레이트콜린 및 스타틴계 약물을 함유하는 약제학적 복합제제
WO2024084496A1 (en) Pharmaceutical compositions comprising acalabrutinib maleate
EP4385502A1 (en) A pharmaceutical formulation comprising metformin, pioglitazone and a sglt-2 inhibitor
WO2023038600A1 (en) A capsule formulation comprising macitentan